Stay updated with breaking news from Asn 23. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Although the DUPLEX trial missed its primary endpoint of eGFR slope in patients with FSGS, results point to greater reductions in proteinuria and in risk of kidney failure with sparsentan use relative to irbesartan—making its case for becoming a standard of care for the glomerular disease.
An analysis of the MIRROR trial from ASN Kidney Week 2023 details the effects of urate-lowering therapy on blood pressure among patients with uncontrolled gout receiving pegloticase plus methotrexate in the phase 4 trial.
An analysis of Target-HTN provides new insight into the effects of lorundrostat among patients with uncontrolled or treatment-resistant hypertension.